AOTMiT: What will the Transparency Council address at its upcoming meeting?

The agenda includes:

1. Preparation of a position paper on the evaluation of the drug Amvuttra (vutrisiran) under the drug program: "Treatment of adult patients with stage I or II polyneuropathy in the course of hereditary transthyretin amyloidosis (ICD-10 E85.1)".
...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at english@medexpress.pl.

If you already have an account, please log in